{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:28:57Z","timestamp":1791268137814,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T00:00:00Z","timestamp":1390176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Osteosarcoma is the most common primary malignant tumor of bone and accounts for around 50% of all primary skeletal malignancies. In addition to novel chemotherapies, there is a need for adjuvant therapies designed to inhibit osteosarcoma proliferation and tumor-induced osteolysis to attenuate tumor expansion and metastasis. As such, studies on the efficacy of bisphosphonates on human osteosarcoma are planned after feasibility studies determined that the bisphosphonate zoledronic acid (ZOL) can be safely combined with conventional chemotherapy. However, the molecular mechanisms responsible for, and means of inhibiting, osteosarcoma-induced osteolysis are largely unknown. We establish that osteosarcoma growth directly correlates with tumor-induced osteolysis and activation of osteoclasts in vivo. In vitro, tumor cells were determined to expresses surface, but not soluble, receptor activator of NF-\u03baB ligand (RANKL) and stimulated osteoclastogenesis in a manner directly proportional to their malignant potential. In addition, an aggressive osteosarcoma cell line was shown to secrete monocyte chemoattractant protein-1 (MCP-1), resulting in robust monocyte migration. Because MCP-1 is a key cytokine for monocyte recruitment and surface-bound RANKL strongly supports local osteoclastogenesis, we suggest that high levels of these signaling molecules are associated with the aggressive potential of osteosarcoma. Consistent with these findings, abundant expression of RANKL\/MCP-1 was observed in tumor in vivo, and MCP-1 plasma levels strongly correlated with tumor progression and osteolysis. ZOL administration directly attenuates osteosarcoma production of RANKL\/MCP-1, reducing tumor-induced bone destruction. In vivo, these findings also correlated with significant reduction in osteosarcoma growth. ZOL attenuates tumor-induced osteolysis, not only through direct inhibition of osteoclasts, but also through direct actions on tumor expression of osteoclast activators. These data provide insight regarding the effect of ZOL on osteosarcoma essential for designing the planned upcoming prospective randomized trials to determine the efficacy of bisphosphonates on osteosarcoma in humans. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2182","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T06:26:44Z","timestamp":1390199204000},"page":"1431-1445","source":"Crossref","is-referenced-by-count":73,"title":["Bisphosphonates Inhibit Osteosarcoma-Mediated Osteolysis Via Attenuation of Tumor Expression of MCP-1 and RANKL"],"prefix":"10.1093","volume":"29","author":[{"given":"Tetsuro","family":"Ohba","sequence":"first","affiliation":[{"name":"Department of OrthopaedicsVanderbilt University Medical CenterNashvilleTNUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of OrthopaedicsVanderbilt University Medical CenterNashvilleTNUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin MM","family":"Cates","sequence":"additional","affiliation":[{"name":"Department of PathologyMicrobiology, and Immunology, Vanderbilt University Medical CenterNashvilleTNUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Slosky","sequence":"additional","affiliation":[{"name":"Department of Cardio-oncologyVanderbilt University Medical CenterNashvilleTNUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Haro","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of MedicineUniversity of YamanashiYamanashiJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of MedicineUniversity of YamanashiYamanashiJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert S","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of OrthopaedicsVanderbilt University Medical CenterNashvilleTNUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G","family":"Schoenecker","sequence":"additional","affiliation":[{"name":"Department of PediatricsVanderbilt University Medical CenterNashvilleTNUSA"},{"name":"Department of PharmacologyVanderbilt University Medical CenterNashvilleTNUSA"},{"name":"Center for Bone BiologyVanderbilt University Medical CenterNashvilleTNUSA"},{"name":"Department of PathologyMicrobiology, and Immunology, Vanderbilt University Medical CenterNashvilleTNUSA"},{"name":"Department of OrthopaedicsVanderbilt University Medical CenterNashvilleTNUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,20]]},"reference":[{"issue":"6","key":"2024020318515863000_jbmr2182-bib-0001","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1470-2045(07)70169-9","article-title":"Opportunities for improving the therapeutic ratio for patients with sarcoma","volume":"8","author":"Wunder","year":"2007","journal-title":"Lancet Oncol."},{"issue":"1","key":"2024020318515863000_jbmr2182-bib-0002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","article-title":"Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis","volume":"48","author":"Lipton","year":"2011","journal-title":"Bone."},{"issue":"10","key":"2024020318515863000_jbmr2182-bib-0003","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/RLI.0b013e31825dddfb","article-title":"Molecular imaging of fibrin in a breast cancer xenograft mouse model","volume":"47","author":"Uppal","year":"2012","journal-title":"Invest Radiol."},{"issue":"6","key":"2024020318515863000_jbmr2182-bib-0004","first-page":"1231","article-title":"Increased osteoclast activity is associated with aggressiveness of osteosarcoma","volume":"33","author":"Avnet","year":"2008","journal-title":"Int J Oncol."},{"issue":"2","key":"2024020318515863000_jbmr2182-bib-0005","first-page":"253","article-title":"VEGF blockade decelerates the growth of a murine experimental osteosarcoma","volume":"33","author":"Yin","year":"2008","journal-title":"Int J Oncol."},{"issue":"4","key":"2024020318515863000_jbmr2182-bib-0006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","article-title":"An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis","volume":"22","author":"Luu","year":"2005","journal-title":"Clin Exp Metastasis."},{"issue":"10","key":"2024020318515863000_jbmr2182-bib-0007","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/jbmr.453","article-title":"Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient","volume":"26","author":"Battaglia","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024020318515863000_jbmr2182-bib-0008","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.ejca.2013.03.018","article-title":"Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"49","author":"Goldsby","year":"2013","journal-title":"Eur J Cancer."},{"issue":"3","key":"2024020318515863000_jbmr2182-bib-0009","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006767007547","article-title":"An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential","volume":"18","author":"Khanna","year":"2000","journal-title":"Clin Exp Metastasis."},{"issue":"3","key":"2024020318515863000_jbmr2182-bib-0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1432-0436.1988.tb00090.x","article-title":"Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma","volume":"39","author":"Schmidt","year":"1988","journal-title":"Differentiation."},{"issue":"9","key":"2024020318515863000_jbmr2182-bib-0011","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/cncr.26518","article-title":"Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma","volume":"118","author":"Ichikawa","year":"2012","journal-title":"Cancer."},{"issue":"19","key":"2024020318515863000_jbmr2182-bib-0012","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"2024020318515863000_jbmr2182-bib-0013","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"2024020318515863000_jbmr2182-bib-0014","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/jor.21474","article-title":"Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis","volume":"29","author":"Cole","year":"2011","journal-title":"J Orthop Res."},{"issue":"6","key":"2024020318515863000_jbmr2182-bib-0015","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1148\/rg.306105524","article-title":"Imaging characteristics of primary osteosarcoma: nonconventional subtypes","volume":"30","author":"Yarmish","year":"2010","journal-title":"Radiographics."},{"issue":"1","key":"2024020318515863000_jbmr2182-bib-0016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1148\/radiol.2331030326","article-title":"Imaging of periosteal osteosarcoma: radiologic-pathologic comparison","volume":"233","author":"Murphey","year":"2004","journal-title":"Radiology."},{"key":"2024020318515863000_jbmr2182-bib-0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.blo.0000229333.98781.56","article-title":"McGough RL 3rd, Huard J. VEGF and BMP expression in mouse osteosarcoma cells","volume":"450","author":"Weiss","year":"2006","journal-title":"Clin Orthop Relat Res."},{"issue":"7355","key":"2024020318515863000_jbmr2182-bib-0018","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature."},{"issue":"11","key":"2024020318515863000_jbmr2182-bib-0019","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1593\/neo.09988","article-title":"The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment","volume":"11","author":"Mizutani","year":"2009","journal-title":"Neoplasia."},{"issue":"3","key":"2024020318515863000_jbmr2182-bib-0020","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun."},{"issue":"1\u20132","key":"2024020318515863000_jbmr2182-bib-0021","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mce.2012.05.002","article-title":"Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras\/MEK\/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2","volume":"361","author":"Tsubaki","year":"2012","journal-title":"Mol Cell Endocrinol."},{"issue":"3","key":"2024020318515863000_jbmr2182-bib-0022","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdr159","article-title":"Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer","volume":"23","author":"Gallo","year":"2012","journal-title":"Ann Oncol."},{"issue":"5","key":"2024020318515863000_jbmr2182-bib-0023","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024020318515863000_jbmr2182-bib-0024","doi-asserted-by":"crossref","first-page":"10683","DOI":"10.3390\/ijms140610683","article-title":"RANK\/RANK-L\/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study","volume":"14","author":"Mercatali","year":"2013","journal-title":"Int J Mol Sci."},{"issue":"9\u201310","key":"2024020318515863000_jbmr2182-bib-0025","first-page":"499","article-title":"Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin Lab."},{"issue":"2","key":"2024020318515863000_jbmr2182-bib-0026","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/path.2869","article-title":"Ewing sarcoma cells express RANKL and support osteoclastogenesis","volume":"225","author":"Taylor","year":"2011","journal-title":"J Pathol."},{"issue":"11","key":"2024020318515863000_jbmr2182-bib-0027","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/sj.bjc.6603774","article-title":"Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma","volume":"96","author":"Lau","year":"2007","journal-title":"Br J Cancer."},{"issue":"1","key":"2024020318515863000_jbmr2182-bib-0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00365510802460466","article-title":"Expression of RANK-ligand in prostate cancer cell lines","volume":"69","author":"Penno","year":"2009","journal-title":"Scand J Clin Lab Invest."},{"issue":"4","key":"2024020318515863000_jbmr2182-bib-0029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2659","article-title":"Vitamin E decreases bone mass by stimulating osteoclast fusion","volume":"18","author":"Fujita","year":"2012","journal-title":"Nat Med."},{"issue":"3","key":"2024020318515863000_jbmr2182-bib-0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev."},{"issue":"2","key":"2024020318515863000_jbmr2182-bib-0031","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell."},{"issue":"1","key":"2024020318515863000_jbmr2182-bib-0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jb\/mvt049","article-title":"Immunology and bone","volume":"154","author":"Danks","year":"2013","journal-title":"J Biochem."},{"issue":"5","key":"2024020318515863000_jbmr2182-bib-0033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pbc.22720","article-title":"RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma","volume":"56","author":"Lee","year":"2011","journal-title":"Pediatr Blood Cancer."},{"issue":"10","key":"2024020318515863000_jbmr2182-bib-0034","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/jbmr.455","article-title":"Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models","volume":"26","author":"Rousseau","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318515863000_jbmr2182-bib-0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2005.04.013","article-title":"MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL","volume":"7","author":"Lynch","year":"2005","journal-title":"Cancer Cell."},{"issue":"6","key":"2024020318515863000_jbmr2182-bib-0036","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s007740200049","article-title":"Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis","volume":"20","author":"Mizuno","year":"2002","journal-title":"J Bone Miner Metab."},{"key":"2024020318515863000_jbmr2182-bib-0037","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther."},{"issue":"9","key":"2024020318515863000_jbmr2182-bib-0038","doi-asserted-by":"crossref","first-page":"e74045","DOI":"10.1371\/journal.pone.0074045","article-title":"Expression of the chemokine receptor CXCR7 in CXCR4-expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice","volume":"8","author":"Brennecke","year":"2013","journal-title":"PLoS One."},{"issue":"4","key":"2024020318515863000_jbmr2182-bib-0039","doi-asserted-by":"crossref","first-page":"e35101","DOI":"10.1371\/journal.pone.0035101","article-title":"CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One."},{"issue":"18","key":"2024020318515863000_jbmr2182-bib-0040","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/0008-5472.CAN-09-4291","article-title":"Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases","volume":"70","author":"Endo-Munoz","year":"2010","journal-title":"Cancer Res."},{"issue":"22","key":"2024020318515863000_jbmr2182-bib-0041","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"115","author":"Chou","year":"2009","journal-title":"Cancer."},{"issue":"9","key":"2024020318515863000_jbmr2182-bib-0042","first-page":"779","article-title":"CC chemokine receptor-coupled signalling pathways","volume":"35","author":"New","year":"2003","journal-title":"Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)."},{"issue":"5","key":"2024020318515863000_jbmr2182-bib-0043","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol."},{"issue":"2","key":"2024020318515863000_jbmr2182-bib-0044","first-page":"434","article-title":"The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis","volume":"1826","author":"Endo-Munoz","year":"2012","journal-title":"Biochim Biophys Acta."},{"issue":"16","key":"2024020318515863000_jbmr2182-bib-0045","doi-asserted-by":"crossref","first-page":"16163","DOI":"10.1074\/jbc.M412713200","article-title":"MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation","volume":"280","author":"Kim","year":"2005","journal-title":"J Biol Chem."},{"issue":"5","key":"2024020318515863000_jbmr2182-bib-0046","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jcb.22799","article-title":"Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer","volume":"111","author":"Bussard","year":"2010","journal-title":"J Cell Biochem."},{"issue":"8","key":"2024020318515863000_jbmr2182-bib-0047","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","article-title":"Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents","volume":"17","author":"Buddingh","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2024020318515863000_jbmr2182-bib-0048","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024020318515863000_jbmr2182-bib-0049","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1186\/ar4018","article-title":"Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis","volume":"14","author":"Kim","year":"2012","journal-title":"Arthritis Res Ther."},{"issue":"7","key":"2024020318515863000_jbmr2182-bib-0050","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/labinvest.3780115","article-title":"Inhibition of monocyte chemotactic protein-1 synthesis by statins","volume":"80","author":"Romano","year":"2000","journal-title":"Lab Invest."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2182","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/6\/1431\/56565084\/jbmr2182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/6\/1431\/56565084\/jbmr2182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:51:30Z","timestamp":1710341490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/29\/6\/1431-1445\/7598853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,20]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,1,20]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2182","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,6,1]]},"published":{"date-parts":[[2014,1,20]]}}}